Amanda Murphy joined the CZ Biohub Chicago as Chief Operating Officer in September 2023. Murphy spent much of her career as a tenured healthcare senior equity research analyst and a partner at William Blair & Company, L.L.C., covering various life sciences services, instrumentation, and biotech companies.
Most recently, she has held various roles across finance and corporate development. As CFO of MaxCyte, she spearheaded cross-over and IPO financings, raising $300 million in capital. Murphy developed corporate development experience as Head of M&A and External Innovation at Ginkgo Bioworks, and served as Chief Development Officer for DA32 Life Science Tech Acquisition Corp (a partnership between Arch Venture Partners, Deerfield Management, and venture capital firm Section 32).
She has an MBA from Northwestern University majoring in accounting, finance, and economics, holds a Chartered Financial Analyst designation, and has a Bachelor of Science from Boston College’s Honors Program.
